These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 21812797

  • 1. Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes.
    Derosa G, Cicero AF, D'Angelo A, Fogari E, Maffioli P.
    J Clin Pharm Ther; 2012 Apr; 37(2):187-95. PubMed ID: 21812797
    [Abstract] [Full Text] [Related]

  • 2. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G, Cicero AF, Murdolo G, Ciccarelli L, Fogari R.
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [Abstract] [Full Text] [Related]

  • 3. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, Franzetti IG, Gadaleta G, Ciccarelli L, Piccinni MN, D'Angelo A, Cicero AF.
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [Abstract] [Full Text] [Related]

  • 4. Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Endocr J; 2010 Jun; 57(9):777-86. PubMed ID: 20683173
    [Abstract] [Full Text] [Related]

  • 5. Comparison of orlistat treatment and placebo in obese type 2 diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Expert Opin Pharmacother; 2010 Aug; 11(12):1971-82. PubMed ID: 20569086
    [Abstract] [Full Text] [Related]

  • 6. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G, Maffioli P, Ferrari I, D'Angelo A, Fogari E, Palumbo I, Randazzo S, Cicero AF.
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [Abstract] [Full Text] [Related]

  • 7. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G, D'Angelo A, Salvadeo SA, Ferrari I, Gravina A, Fogari E, Maffioli P, Cicero AF.
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [Abstract] [Full Text] [Related]

  • 8. Effect of orlistat on cardiovascular disease risk in obese adults.
    Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.
    Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss.
    Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M.
    Curr Med Res Opin; 2005 Nov; 21(11):1885-90. PubMed ID: 16307710
    [Abstract] [Full Text] [Related]

  • 11. Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Pharm Pharm Sci; 2010 Nov; 13(3):378-90. PubMed ID: 21092710
    [Abstract] [Full Text] [Related]

  • 12. Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
    Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, D'Angelo A, Palumbo I, Randazzo S, Cicero AF.
    Intern Med; 2010 Nov; 49(16):1717-25. PubMed ID: 20720348
    [Abstract] [Full Text] [Related]

  • 13. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Kuo CS, Pei D, Yao CY, Hsieh MC, Kuo SW.
    Int J Clin Pract; 2006 Aug; 60(8):906-10. PubMed ID: 16893433
    [Abstract] [Full Text] [Related]

  • 14. Short-term administration of orlistat reduced daytime triglyceridemia in obese women with the metabolic syndrome.
    Tzotzas T, Samara M, Constantinidis T, Tziomalos K, Krassas G.
    Angiology; 2007 Aug; 58(1):26-33. PubMed ID: 17351155
    [Abstract] [Full Text] [Related]

  • 15. [Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].
    Zhang XJ, Wang Z, Li HH, Yu L, Gao S.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1393-6. PubMed ID: 21223671
    [Abstract] [Full Text] [Related]

  • 16. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [Abstract] [Full Text] [Related]

  • 17. A randomized double-blind study comparing the efficacy and safety of orlistat versus placebo in obese patients with mild to moderate hypercholesterolemia.
    de Castro JJ, Dias T, Chambel P, Carvalheiro M, Correia LG, Guerreiro L, Marques O, Medina JL, Nobre E, Nunes JS, Pereiraa MC, Polónia J, Portugal J, Raimundo A, Ruas A, da Silva PM, Vasconcelos C, Reis JL, Teles AG.
    Rev Port Cardiol; 2009 Dec; 28(12):1361-74. PubMed ID: 20301983
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
    Derosa G, Maffioli P, Ferrari I, Palumbo I, Randazzo S, D'Angelo A, Cicero AF.
    J Clin Pharm Ther; 2011 Oct; 36(5):592-601. PubMed ID: 21070297
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.